Skip to main content
KLRA logo

Kailera Therapeutics, Inc.

KLRANASDAQHealthcareBiotechnology

$11.25Today:- (-)

As of Oct 16, 2026 close

Market cap
$1.20B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$9.76$28.23
Volume (live)
-
Avg. volume (3M)
1.34M

Kailera Therapeutics (KLRA) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Kailera Therapeutics used $120.21M of cash in operating activities and spent $2.09M on capital expenditures. That left free cash flow of −$122.30M.

Kailera Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Kailera Therapeutics, Inc. (KLRA) - Annual data in millions USD
BreakdownFY 2025FY 2024
Period endingDec 2025Dec 2024
Operating Activities
Net Income-148.96-329.57
Depreciation & Amortization0.310.08
Stock Based Compensation10.941.41
Change in Working Capital16.783.62
Change in Accounts Payable4.693.01
Change in Other Working Capital0.660.61
Other Operating Activities0.66139.50
Net Cash from Operating Activities-120.21-184.95
Investing Activities
Capital Expenditures-2.09-0.39
Purchases of Investments-632.16-
Sales/Maturities of Investments141.65-
Net Cash from Investing Activities-492.60-0.39
Financing Activities
Debt Repayment100.00-
Common Stock Issued498.87-
Other Financing Activities-0.32-
Net Cash from Financing Activities598.66448.11
Summary
Net Change in Cash-14.15262.77
Cash at Beginning of Period175.18-
Cash at End of Period161.03-
Free Cash Flow-122.30-185.35

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Kailera Therapeutics Cash Flow

What is Kailera Therapeutics's free cash flow?

Kailera Therapeutics had negative free cash flow of $122.30M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$120.21M minus $2.09M of capital expenditures.

How much does Kailera Therapeutics spend on capital expenditures?

Kailera Therapeutics spent $2.09M on capital expenditures in fiscal 2025, compared with $393.00K a year earlier.

Does Kailera Therapeutics pay dividends or buy back shares?

Kailera Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition